Tyra Biosciences, Inc. (TYRA)
NASDAQ: TYRA · Real-Time Price · USD
35.06
-1.86 (-5.04%)
At close: Apr 28, 2026, 4:00 PM EDT
34.65
-0.41 (-1.17%)
After-hours: Apr 28, 2026, 6:54 PM EDT
Tyra Biosciences Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Tyra Biosciences stock have an average target of 47.5, with a low estimate of 30 and a high estimate of 59. The average target predicts an increase of 35.48% from the current stock price of 35.06.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Tyra Biosciences stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 3 | 4 | 4 | 6 |
| Buy | 3 | 2 | 3 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 6 | 6 | 9 | 9 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Initiates $54 | Strong Buy | Initiates | $54 | +54.02% | Apr 15, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +42.61% | Apr 6, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $42 → $56 | Buy | Maintains | $42 → $56 | +59.73% | Mar 20, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Feb 24, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $45 | Strong Buy | Maintains | $30 → $45 | +28.35% | Feb 17, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.47
from -2.01
EPS Next Year
-2.68
from -2.47
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.15 | -2.14 | ||||||
| Avg | -2.47 | -2.68 | ||||||
| Low | -2.61 | -2.99 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.